Who are Lumacaftor plus Ivacaftor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ivacaftor+lumacaftor, LUM/IVA, Placebo matched to VX-661/ ivacaftor.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lumacaftor-plus-ivacaftor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Lumacaftor plus Ivacaftor — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lumacaftor plus Ivacaftor (Lumacaftor plus Ivacaftor) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CFTR modulator combination (corrector + potentiator). Area: Pulmonary / Cystic Fibrosis.

phase 3 CFTR modulator combination (corrector + potentiator) CFTR (cystic fibrosis transmembrane conductance regulator) Pulmonary / Cystic Fibrosis Small molecule Live · refreshed every 30 min

Target snapshot

Lumacaftor plus Ivacaftor (Lumacaftor plus Ivacaftor) — Hannover Medical School. Lumacaftor and ivacaftor work together to correct the misfolding and trafficking of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, restoring its function at the cell surface.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lumacaftor plus Ivacaftor TARGET	Lumacaftor plus Ivacaftor	Hannover Medical School	phase 3	CFTR modulator combination (corrector + potentiator)	CFTR (cystic fibrosis transmembrane conductance regulator)
Ivacaftor+lumacaftor	Ivacaftor+lumacaftor	Assistance Publique - Hôpitaux de Paris	marketed	CFTR modulator combination (corrector + potentiator)	CFTR (cystic fibrosis transmembrane conductance regulator)
LUM/IVA	LUM/IVA	Vertex Pharmaceuticals Incorporated	marketed	CFTR modulator combination (corrector + potentiator)	CFTR (cystic fibrosis transmembrane conductance regulator)
Placebo matched to VX-661/ ivacaftor	Placebo matched to VX-661/ ivacaftor	Vertex Pharmaceuticals Incorporated	phase 3	CFTR modulator combination (corrector + potentiator)	CFTR (Cystic Fibrosis Transmembrane Conductance Regulator)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CFTR modulator combination (corrector + potentiator) class)

Vertex Pharmaceuticals Incorporated · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Hannover Medical School · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lumacaftor plus Ivacaftor — Competitive Intelligence Brief. https://druglandscape.com/ci/lumacaftor-plus-ivacaftor. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab